[Translation] A randomized, double-blind, placebo-controlled, phase III study evaluating Debio 1143 in combination with platinum-based chemotherapy and standard fractionated intensity-modulated radiotherapy in patients with locally advanced head and neck squamous cell carcinoma who are candidates for definitive chemoradiotherapy (TrilynX)
主要目的:在LA-SCCHN中证实在CRT的基础上添加Debio 1143相比于安慰剂的优效性。
次要目的:根据额外的有效性终点,评估在CRT基础上添加Debio 1143相比于安慰剂的有效性。评估在CRT基础上添加Debio 1143相比于安慰剂的安全性、耐受性和治疗依从性。使用患者自报结局问卷,评估在CRT基础上添加Debio 1143相比于安慰剂的健康相关生活质量。
[Translation] Primary Objective: To demonstrate the superiority of Debio 1143 added to CRT compared to placebo in LA-SCCHN.
Secondary Objectives: To evaluate the effectiveness of Debio 1143 added to CRT compared to placebo based on additional efficacy endpoints. To evaluate the safety, tolerability, and treatment compliance of Debio 1143 added to CRT compared to placebo. To evaluate the health-related quality of life of Debio 1143 added to CRT compared to placebo using a patient-reported outcomes questionnaire.